Published in J Clin Invest on April 15, 2013
Diversification of TAM receptor tyrosine kinase function. Nat Immunol (2014) 2.12
Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer. Proc Natl Acad Sci U S A (2013) 1.64
Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci U S A (2015) 1.51
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities. Elife (2014) 1.11
Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia. Blood (2013) 1.00
UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J Med Chem (2014) 0.99
Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity. J Biol Chem (2014) 0.97
Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. J Med Chem (2013) 0.96
Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. J Med Chem (2013) 0.91
Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Oncotarget (2015) 0.88
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov (2014) 0.88
Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer. Mol Cancer Ther (2015) 0.87
Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer. Inflamm Bowel Dis (2014) 0.84
Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget (2014) 0.82
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas. Oncotarget (2016) 0.80
Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow. Oncotarget (2016) 0.80
Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib. Oncotarget (2015) 0.80
B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells. Oncotarget (2014) 0.79
MERTK as a novel therapeutic target in head and neck cancer. Oncotarget (2016) 0.79
MERTK as negative regulator of human T cell activation. J Leukoc Biol (2015) 0.79
Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status. Mol Cancer Ther (2015) 0.79
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight (2016) 0.78
Mammary epithelial cell phagocytosis downstream of TGF-β3 is characterized by adherens junction reorganization. Cell Death Differ (2015) 0.76
Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies. Cancer Res (2016) 0.76
The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors. Pigment Cell Melanoma Res (2015) 0.76
Molecular insights of Gas6/TAM in cancer development and therapy. Cell Death Dis (2017) 0.76
MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme. PLoS One (2016) 0.76
Nanoparticle-motivated gene delivery for ophthalmic application. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.76
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies. Curr Oncol Rep (2017) 0.75
Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity. Sci Rep (2017) 0.75
The Gas6/TAM System and Multiple Sclerosis. Int J Mol Sci (2016) 0.75
Ligand Activation of TAM Family Receptors-Implications for Tumor Biology and Therapeutic Response. Cancers (Basel) (2016) 0.75
Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma. Sci Rep (2017) 0.75
Analysis of PI3K pathway components in human cancers. Oncol Lett (2016) 0.75
Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy. Oncotarget (2016) 0.75
Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL. Oncotarget (2017) 0.75
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
NCBI GEO: archive for functional genomics data sets--10 years on. Nucleic Acids Res (2010) 14.38
A landscape of driver mutations in melanoma. Cell (2012) 12.61
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Melanoma biology and new targeted therapy. Nature (2007) 10.71
Melanoma. N Engl J Med (2006) 8.80
Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med (2002) 8.04
Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76
Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature (2001) 6.31
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun (2012) 4.94
V599EB-RAF is an oncogene in melanocytes. Cancer Res (2004) 4.49
Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med (2006) 4.47
TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res (2008) 3.63
The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics (2008) 3.11
A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood (2006) 2.41
Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol (2011) 2.09
Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol (2011) 2.09
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One (2011) 1.89
Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther (2010) 1.69
Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res (2006) 1.61
Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res (2009) 1.42
Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res (2011) 1.38
Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol (2011) 1.35
Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene (2012) 1.33
Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. ACS Med Chem Lett (2012) 1.22
Signal pathways in up-regulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer Res (2004) 1.12
Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology. Oncogene (2011) 1.07
Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol (2010) 1.05
A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci U S A (2009) 1.04
Reviewing the somatic genetics of melanoma: from current to future analytical approaches. Pigment Cell Melanoma Res (2012) 1.02
A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines. Pigment Cell Melanoma Res (2012) 0.97
Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus. PLoS One (2012) 0.93
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell (2009) 11.36
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
R2D2, a bridge between the initiation and effector steps of the Drosophila RNAi pathway. Science (2003) 9.53
The BioGRID Interaction Database: 2011 update. Nucleic Acids Res (2010) 8.46
Comparative genome sequencing of Drosophila pseudoobscura: chromosomal, gene, and cis-element evolution. Genome Res (2005) 8.38
Identification of cells initiating human melanomas. Nature (2008) 8.28
Sunitinib: from rational design to clinical efficacy. J Clin Oncol (2007) 7.26
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell (2005) 6.86
TNF-alpha induces two distinct caspase-8 activation pathways. Cell (2008) 6.81
Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell (2012) 6.56
Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell (2005) 6.47
Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev (2003) 6.17
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Cytochrome C-mediated apoptosis. Annu Rev Biochem (2004) 5.38
Specific ablation of the apoptotic functions of cytochrome C reveals a differential requirement for cytochrome C and Apaf-1 in apoptosis. Cell (2005) 5.37
WormBase: a comprehensive resource for nematode research. Nucleic Acids Res (2009) 5.20
Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell (2007) 5.09
Jaundice Constrain or Indication? Response. Radiology (2017) 5.07
A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science (2004) 4.95
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 4.82
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68
Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med (2011) 4.68
Chronic traumatic encephalopathy in a National Football League player. Neurosurgery (2005) 4.67
SPARX, a new environment for Cryo-EM image processing. J Struct Biol (2006) 4.66
Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA. Cell Res (2011) 4.55
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet (2009) 4.52
The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways. Cell (2012) 4.37
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
WormBase: new content and better access. Nucleic Acids Res (2006) 4.01
Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol (2012) 4.00
Ribonomics: identifying mRNA subsets in mRNP complexes using antibodies to RNA-binding proteins and genomic arrays. Methods (2002) 3.92
WormBase 2012: more genomes, more data, new website. Nucleic Acids Res (2011) 3.87
The complete genomes and proteomes of 27 Staphylococcus aureus bacteriophages. Proc Natl Acad Sci U S A (2005) 3.84
Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med (2002) 3.83
Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project. Stroke (2008) 3.81
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77
WormBase 2007. Nucleic Acids Res (2007) 3.69
TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res (2008) 3.63
Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc Natl Acad Sci U S A (2004) 3.63
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol (2011) 3.60
Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science (2003) 3.59
Quantitative susceptibility map reconstruction from MR phase data using bayesian regularization: validation and application to brain imaging. Magn Reson Med (2010) 3.43
Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res (2010) 3.30
Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol (2007) 3.23
Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol (2002) 3.07
Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol Cell (2002) 3.06
Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis. Proc Natl Acad Sci U S A (2009) 3.00
The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell (2010) 2.97
Too many roads not taken. Nature (2011) 2.93
Smoking during pregnancy and newborn neurobehavior. Pediatrics (2003) 2.93
Clinical applications of metabolomics in oncology: a review. Clin Cancer Res (2009) 2.91
The integrated response of the human cerebro-cerebellar and limbic systems to acupuncture stimulation at ST 36 as evidenced by fMRI. Neuroimage (2005) 2.86
Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell (2012) 2.83
Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. Circulation (2004) 2.81
Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han population. Biol Psychiatry (2005) 2.79
Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res (2004) 2.79
Indirect emissions from biofuels: how important? Science (2009) 2.71
Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis. Am J Gastroenterol (2012) 2.70
Characterization of the "deqi" response in acupuncture. BMC Complement Altern Med (2007) 2.70
Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. Proc Natl Acad Sci U S A (2011) 2.64
Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china. Circ Cardiovasc Qual Outcomes (2010) 2.63
Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro (2005) 2.60
Emerging histomorphologic phenotypes of chronic traumatic encephalopathy in American athletes. Neurosurgery (2011) 2.59
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol (2008) 2.57
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol (2006) 2.51
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol (2007) 2.51
H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. Nat Genet (2012) 2.47
Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J Immunol (2007) 2.45
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood (2006) 2.41
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41
Chronic traumatic encephalopathy in a national football league player: part II. Neurosurgery (2006) 2.40
WormBase 2014: new views of curated biology. Nucleic Acids Res (2013) 2.39
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol (2011) 2.39
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol (2009) 2.36
Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A (2007) 2.34
Whole-slide imaging digital pathology as a platform for teleconsultation: a pilot study using paired subspecialist correlations. Arch Pathol Lab Med (2009) 2.30
A cross-sectional study of the microeconomic impact of cardiovascular disease hospitalization in four low- and middle-income countries. PLoS One (2011) 2.23
Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol (2005) 2.22
Mutant DNA-binding domain of HSF4 is associated with autosomal dominant lamellar and Marner cataract. Nat Genet (2002) 2.21
The role of oxygen during fracture healing. Bone (2012) 2.21
Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J Clin Invest (2003) 2.20
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest (2003) 2.19
Comparative genomic analysis of 18 Pseudomonas aeruginosa bacteriophages. J Bacteriol (2006) 2.18
Formation of apoptosome is initiated by cytochrome c-induced dATP hydrolysis and subsequent nucleotide exchange on Apaf-1. Proc Natl Acad Sci U S A (2005) 2.18